Omada Health, Inc. OMDA
Set alert
18.73 USD -0.92 -4.68%
At close · Oct 30
18.73 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
18.47 Day range 19.47
10.94 52-week range 25.67
- YTD
- +18.69%
- 1 year
- -22.79%
- Open
- 19.35
- Prev close
- 19.65
- Mkt cap
- 1.15B
- Vol
- 958.63K
- Avg vol
- 1.33M
- EPS
- 0.24
- P/E
- 78.04
- Div yield
- 0.00%
More statistics
- Low
- 18.47
- High
- 19.47
- Forward P/E
- 33.68
- Beta
- 0.00
- Short ratio
- 5.58
- Inst. own
- 88.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 20.85
- 200-d avg
- 17.67
- 1y target
- 28.17
5Y chart
Events in this range
- Aug 7, 2025Earnings: -0.09; estimate -0.1; surprise 10%
- Nov 6, 2025Earnings: -0.06; estimate -0.1; surprise 40%
- Mar 5, 2026Earnings: 0.13; estimate 0.03; surprise 333.33%
- May 7, 2026Earnings: 0.01; estimate -0.08; surprise 112.5%
- Aug 6, 2026Earnings: 0.15; estimate 0.0622; surprise 141.16%
- Sep 11, 2026Rating: BTIG · Buy → Buy
- Sep 11, 2026Rating: Needham · Buy → Buy
- Sep 11, 2026Rating: Barclays · Overweight → Overweight
- Sep 14, 2026Rating: Freedom Capital Markets · Buy → Buy
- Oct 14, 2026Rating: Freedom Capital Markets · Buy → Buy
- Oct 28, 2026Rating: Barclays · Overweight → Overweight
- Nov 5, 2026Earnings: —; estimate 0.06939; surprise —%
Signals (14)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 16, 2026 | 7 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
Key statistics
- Market cap
- 1.15B
- Enterprise value
- 981.20M
- Trailing P/E
- 78.04
- Forward P/E
- 33.68
- PEG ratio
- 0.00
- Price / sales
- 3.70
- Price / book
- 4.49
- EPS (TTM)
- 0.24
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 1.39%
- Revenue (TTM)
- 309.76M
- Revenue growth
- 43.10%
- Free cash flow
- 11.92M
- Total cash
- 221.71M
- Total debt
- 0
- Return on equity
- 1.84%
- Shares outstanding
- 61.22M
- Short % of float
- 13.89%
- 50-day average
- 20.85
- 200-day average
- 17.67
Analyst view
Consensus: buy
Buy
Price target (mean) 28.17 +50.4% upside
Now 18.73
- Target (low)
- 22.00
- Target (mean)
- 28.17
- Target (high)
- 35.00
Ratings (0m) 12 10 buy · 2 hold · 0 sell
- Strong buy5
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.0981.
Financials — quick view
OMDA Revenue — quarterly 87.83M
OMDA Net income — quarterly 5.29M
OMDA EPS — quarterly 0.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.06939 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.0622 | 0.15 | +0.09 | +141.16% |
| May 7, 2026 | Mar 31, 2026 | -0.08 | 0.01 | +0.09 | +112.50% |
| Mar 5, 2026 | Dec 31, 2025 | 0.03 | 0.13 | +0.10 | +333.33% |
| Nov 6, 2025 | Sep 30, 2025 | -0.10 | -0.06 | +0.04 | +40.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.10 | -0.09 | +0.01 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Barclays | main | Overweight | Overweight |
| Oct 14, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 14, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 11, 2026 | Barclays | main | Overweight | Overweight |
| Sep 11, 2026 | Needham | reit | Buy | Buy |
| Sep 11, 2026 | BTIG | reit | Buy | Buy |
About Omada Health, Inc.
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- omadahealth.com
News
- Barclays Maintains Overweight on Omada Health, Lowers Price Target to $24
- Omada Health To Present Published Research Showing That Members Of Its GLP-1 Care Track Lost More Weight And Experienced Greater Improvements In Body Composition Than GLP-1 Users Receiving Usual Care
- Transcript: Omada Health Q2 2026 Earnings Conference Call
- Barclays Maintains Overweight on Omada Health, Raises Price Target to $27
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- JP Morgan Maintains Overweight on Omada Health, Raises Price Target to $30
- Citizens Maintains Market Outperform on Omada Health, Raises Price Target to $32
- Baird Maintains Neutral on Omada Health, Raises Price Target to $25
- BTIG Maintains Buy on Omada Health, Raises Price Target to $35
- Omada Health Raises FY2026 Sales Guidance from $322.000M-$330.000M to $334.000M-$340.000M vs $327.789M Est
Your note
Sign in to keep a note on OMDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEAL ANNE | Director | Stock Award(Grant) | Jun 15, 2026 | 20,618 |
| COOK STEVEN L. | Chief Financial Officer | Sale | Sep 9, 2026 | 173,906 |
| DUFFY SEAN P | Chief Executive Officer | Sale | Sep 30, 2026 | 1,234,250 |
| FETTER TREVOR | Director | Stock Award(Grant) | Jul 1, 2026 | 135,621 |
| HILLEMAN JERYL L | Director | Stock Award(Grant) | Jul 1, 2026 | 26,519 |
| JAIN SACHIN H. | Director | Stock Award(Grant) | Jun 15, 2026 | 20,618 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Revelation Capital Management, LLC | 7.94% | 4,858,034 | 90.99M | Jun 29, 2026 |
| Divisadero Street Capital Management, LP | 6.21% | 3,799,695 | 71.17M | Jun 29, 2026 |
| American Century Companies Inc | 6.01% | 3,678,676 | 68.90M | Jun 29, 2026 |
| Cigna Investments Inc/New | 5.63% | 3,444,629 | 64.52M | Sep 29, 2026 |
| Morgan Stanley | 4.58% | 2,800,887 | 52.46M | Jun 29, 2026 |
| FMR, LLC | 4.53% | 2,775,102 | 51.98M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 4.60% | 2,814,454 | 52.71M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 1,776,051 | 33.27M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.02% | 1,233,544 | 23.10M | Sep 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.65% | 1,012,400 | 18.96M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.65% | 1,007,298 | 18.87M | Aug 30, 2026 |
| LOOMIS SAYLES FUNDS II-Loomis Sayles Small Cap Growth Fund | 1.41% | 865,078 | 16.20M | Jun 29, 2026 |